Early Bird Registration Deadline for the ICNC has been extended toJULY 15, 2022
This symposium’s objective is to update the child neurology community on the emerging and rapidly expanding spectrum of MOG AB associated neurological disease. This would be predominantly clinician-centric and would help the participants in getting updated information on the diagnostic and therapeutic challenges the clinician faces in taking care of this newly described inflammatory demyelination disorder (IDD) of the central nervous system with myriad presentations.
- Identify the different clinical situations where one should consider MOG antibody associated neurological diseases in the clinic and in the ICU.
- Familiarize themselves with the imaging features that distinguish MOG AB associated IDDs from AQP-4 associated NMOSD and from MS and learn how to differentiate these different syndromes.
- Learn about the challenges of the detection of MOG ABs and also gat an overview of how these antibodies cause disease.
- Decide the why, when and how to manage these disorders n the acute stage and in the long-term.
- Give long-term prognosis to parents about risk of relapse and any persisting deficits expected.
- Diagnosis and differential diagnosis of MOG – associated Neurological Disorders.
- Treatment strategies in the different MOG associated disorders.
Organizer: Vrajesh Udani, MD
Hinduja Hospital & Medical Research Centre, Mumbai, India
Overview of the MOG Antibody Associated IDDs and Challenges in Laboratory Diagnosis
Vrajesh Udani, MD
Clinical and Imaging Features of the MOG Associated IDDs
Russell Dale, MRCP, PhD; Children’s Hospital at Westmead, University of Sydney, Sydney, NSW, Australia
Update on Current Management Strategies and Outcome in the MOG Associated IDDs
Yael Hacohen, MD; Great Ormond Street Hospital for Children, London, United Kingdom
Panel Discussion – Case Scenarios
Neelu Desai, MD, DNB; PD Hinduja Hospital & Medical Research Centre, Mumbai, India